Back to Journals » International Journal of Nanomedicine » Volume 14

A new strategy for accurate targeted diagnosis and treatment of cutaneous malignant melanoma: dual-mode phase-change lipid nanodroplets as ultrasound contrast agents

Authors Yang H, Cai W, Lv W, Zhao P, Shen Y, Zhang L, Ma B, Yuan L, Duan Y, Yao K

Received 3 March 2019

Accepted for publication 1 July 2019

Published 2 September 2019 Volume 2019:14 Pages 7079—7093

DOI https://doi.org/10.2147/IJN.S207419

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 2

Editor who approved publication: Dr Mian Wang


Hengli Yang,1,2,* Wenbin Cai,3,* Wei Lv,2 Ping Zhao,2 Yamei Shen,4 Longfang Zhang,1 Bin Ma,1 Lijun Yuan,2 Yunyou Duan,2 Kechun Yao1

1Department of Ultrasound Diagnosis, Air Force General Hospital, Beijing, People’s Republic of China; 2Department of Ultrasound Diagnosis, Tang Du Hospital, Fourth Military Medical University, Xi’an, People’s Republic of China; 3Special Diagnosis Department, General Hospital of Tibet Military Command, Lhasa, People’s Republic of China; 4Department of Ultrasound Diagnosis, Shaanxi Provincial People’s Hospital, Xi’an, People’s Republic of China

*These authors contributed equally to this work

Correspondence: Yunyou Duan
Department of Ultrasound Diagnosis, Tang Du Hospital, Fourth Military Medical University, Xi’an 710038, People’s Republic of China
Email duanyy@fmmu.edu.cn

Kechun Yao
Department of Ultrasound Diagnosis, Air Force General Hospital, Beijing 100036, People’s Republic of China
Email yaokc1959@hotmail.com

Background: Currently, effective detection and treatment of cutaneous malignant melanoma (CMM) still face severe challenges. Ultrasound molecular imaging as a noninvasive and easy-to-operate method is expected to bring improvements for tumor detection.
Purpose: The aim of this research is to prepare novel phase-change ultrasound contrast agents, Nds-IR780, which can perform not only dual-mode molecule-targeted imaging but also targeted photothermal therapy for CMM.
Methods: A double emulsion process was used to prepare the Nds-IR780. Then, the entrapment rate and drug loading of IR-780 iodide in Nds-IR780 were detected by high-performance liquid chromatography. The biocompatibility of Nds-IR780 was evaluated by a CCK-8 assay and the characteristics and stability of that were verified through the particle size analyzer, laser scanning confocal microscopy (LSCM) and transmission electron microscopy (TEM). The abilities of dual-mode molecule-targeted imaging and targeted photothermal therapy for Nds-IR780 were confirmed via the in vitro and in vivo experiments.
Results: Nds-IR780 had good size distribution, polydispersity index, stability and biosafety. The in vitro and in vivo experiments confirmed that Nds-IR780 were capable of targeting CMM cells with high affinity (22.4±3.2%) and facilitating dual-mode imaging to detect the primary lesion and sentinel lymph nodes (SLNs) of CMM. Furthermore, the photothermal ablation of CMM mediated by Nds-IR780 was very effective in vivo.
Conclusion: The newly prepared Nds-IR780 were observed to be effective targeted theranostic probe for the precise detection and targeted treatment of CMM.

Keywords: CMM, dual-mode phase-change nanodroplets, targeted accurate diagnosis and treatment

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]